Investing.com - Catalyst Pharmaceuticals (NASDAQ: CPRX) reported fourth quarter EPS of $0.530, $0.26 better than the analyst estimate of $0.270. Revenue for the quarter came in at $110.57M versus the consensus estimate of $106.13M.
Catalyst Pharmaceuticals's stock price closed at $14.560. It is down -1.750% in the last 3 months and down -5.820% in the last 12 months.
Catalyst Pharmaceuticals saw 2 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Catalyst Pharmaceuticals's stock price’s past reactions to earnings here.
According to InvestingPro, Catalyst Pharmaceuticals's Financial Health score is "great performance".
Check out Catalyst Pharmaceuticals's recent earnings performance, and Catalyst Pharmaceuticals's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar